Active Ingredient History
Baclofen (brand names Kemstro, Lioresal, and Gablofen) is a derivative of gamma-aminobutyric acid (GABA). Baclofen is a muscle relaxer and an antispastic agent and is used to treat muscle symptoms caused by multiple sclerosis, including spasm, pain, and stiffness. It is primarily used to treat spasticity and is under investigation for the treatment of alcoholism. Although baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects. Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses. Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubjective variation in absorption and/or elimination. Baclofen is a direct agonist at GABA-B receptors. The precise mechanism of action of baclofen is not fully known. It is capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Pain (Phase 2/Phase 3)
Alcohol Drinking (Phase 2)
Alcohol-Induced Disorders (Phase 2)
Alcoholism (Phase 4)
Alcohol Withdrawal Delirium (Phase 4)
Analgesia (Phase 2/Phase 3)
Anterior Cruciate Ligament Injuries (Phase 1/Phase 2)
Anxiety Disorders (Phase 2)
Ataxia Telangiectasia (Early Phase 1)
Autistic Disorder (Phase 1)
Brain Injuries, Traumatic (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Charcot-Marie-Tooth Disease (Phase 3)
Cheyne-Stokes Respiration (Phase 1)
Cocaine-Related Disorders (Phase 2)
Coma (Phase 2)
Constipation (Phase 4)
Crying (Phase 4)
Fibrosis (Phase 2)
Gastroesophageal Reflux (Phase 4)
Genital Diseases, Female (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
Hemiplegia (Phase 4)
Hepatitis C (Phase 4)
Hiccup (Phase 4)
Hypoxia, Brain (Phase 2)
Leukemia (Phase 3)
Liver Cirrhosis, Alcoholic (Phase 1/Phase 2)
Liver Diseases, Alcoholic (Phase 3)
Low Back Pain (Phase 4)
Lower Urinary Tract Symptoms (Phase 4)
Lymphoma (Phase 3)
Lymphoproliferative Disorders (Phase 3)
Marijuana Abuse (Phase 2)
Multiple Myeloma (Phase 3)
Muscle Cramp (Phase 2)
Muscle Hypertonia (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Neoplasms (Phase 3)
Obesity (Phase 1)
Opioid-Related Disorders (Phase 4)
Osteoarthritis (Early Phase 1)
Osteoarthritis, Knee (Phase 2/Phase 3)
Pain (Phase 4)
Pharmacokinetics (Phase 1)
Primary Dysautonomias (Phase 2)
Rumination, Cognitive (Phase 4)
Sleep (Phase 4)
Smoking (Phase 2)
Spinal Cord Injuries (Phase 2)
Stomach Diseases (Phase 4)
Stroke (Phase 4)
Substance-Related Disorders (Early Phase 1)
Substance Withdrawal Syndrome (Phase 1)
Tobacco Use Disorder (Phase 2)
Urinary Bladder, Overactive (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
